A concerted campaign to unlock the use of cannabis to treat severe childhood epilepsy prompted the British authorities last year to sanction its use in certain patients, when other medicines have failed, after consultation with a specialist doctor. On Thursday, NHS England and cost-effectiveness watchdog NICE unveiled their preliminary recommendations on the adoption of cannabis-derived medicines for a variety of conditions. In short, they want more research to justify the medical use of cannabis.
NHS England issued a review that underscored a paucity of long-term safety and efficacy of medicinal cannabis, acknowledging that clinicians have found that some patients with severe treatment-resistant epilepsy do respond to cannabis-based therapy and that observational data suggests cannabis therapy can diminish seizure frequency, fewer trips to emergency rooms and a better quality of life.
While medicinal cannabis was being considered on a case-by-case basis since last November, the lack of randomized control trial (RCT) data